Rethinking Phase I Oncology Trials: New Options and Considerations - IQVIA HOLDINGS INC

Financial Performance:

• No specific corporate financial metrics (revenue, earnings, debt) were reported, as the event is a symposium on clinical trial methodology rather than a corporate earnings call.
• IQVIA Institute data indicates a significant shift in R&D spending sponsorship: large pharma's share of Phase 1 oncology trials dropped from ~50% a decade ago to ~17% in 2025, while emerging biopharma (spending <$200M/year) and pre-commercial entities have surged.
• Global Phase 1 trial success rates for oncology average ~42% over the last five years, contributing to a composite program success rate of ~6%.
• Median time to enrollment for oncology Phase 1 trials is currently 26 months (down from 30 months during the pandemic), and the total median program duration is 10.6 years (up from ~6 years in 2016), with Phase 1 itself consuming ~3.4 years.

Guidance and Future Outlook:

• Panelists aim for a reduction in Phase 1 cycle times, with specific internal goals to reduce decision-making time from 3+ years to under 2 years.
• Long-term optimism exists that common cancers will transition into chronic diseases, driven by improved Phase 1 design and biomarker integration.
• The industry anticipates a shift from "Maximum Tolerated Dose" (MTD) finding to "Optimal Biological Dose" strategies to better inform development.
• Regulatory agencies globally (FDA, EMA, PMDA, NMPA) are engaging in "regulatory competition" to streamline approval pathways, reduce timelines, and attract global trial investment.
• Future growth is expected to come from emerging biotechs and China-based sponsors, necessitating agile global trial designs that integrate data from the Americas, EU, and Asia early.

Business Segments and Product Lines:

• Trial modalities have shifted toward complex targets: Cell and Gene Therapies, Antibody-Drug Conjugates (ADCs), and RNA therapies now represent ~33% of Phase 1 starts.
• Traditional small molecules and other biologics remain at ~45-47% of the market.
• There is a rising trend in "Me Too" or incremental drugs (e.g., ~20 PDL/VEGF bispecifics, multiple ADCs), creating market congestion and resource strain compared to truly novel mechanisms like personalized vaccines and viral immunotherapies.
• Complex trial designs, including umbrella, basket, and master protocols, are being utilized but face adoption barriers, particularly for small biotechs lacking capital for combination studies.

Market and Competitive Landscape:

• China has emerged as a dominant force in Phase 1 trial sponsorship, rising from 17% in 2016 to 43% in 2025; the U.S. holds ~31%.
• Europe remains a key site for trials (led by Spain), while Australia has become a significant emerging hub.
• The US faces a chronic recruitment deficit (~3% enrollment rate for decades) and high bureaucracy, while Europe is attempting to reverse declining competitiveness through regulatory fast-tracks (e.g., in Spain).
• Regulatory competition is intensifying as agencies strive to reduce timelines and improve site accessibility to maintain market share against China and the US.

Risks and Challenges:

• Operational complexity has surged due to targeted agents requiring biomarker-enriched populations, leading to higher screening failure rates and the need for many more sites (15-20 vs. 3-4 in the past).
• Bureaucratic burdens, including lengthy consent forms (50+ pages) and excessive data queries, are diverting site resources from patient care to administration.
• Reimbursement hurdles in the US and Europe for standard-of-care drugs administered during trials are significantly inflating costs and discouraging physician participation.
• Funding gaps exist for small biotechs to pursue novel combination trials, often forcing reliance on partnerships with larger entities.
• Regulatory fragmentation in Europe (e.g., IVDR legislation) is delaying diagnostic validation and trial initiation for HLA-restricted therapies.

Management Commentary and Tone:

• The tone is cautiously optimistic, acknowledging severe structural inefficiencies and a "mess" of repetitive drug development, yet confident that targeted approaches and technology will yield better patient outcomes.
• Management across the panel (investigators, biotech CEOs, CROs) emphasized that the primary goal is accelerating drugs to patients while maintaining scientific rigor.
• A strong sentiment exists that "success" in Phase 1 no longer equates to safety data alone but requires generating actionable data to de-risk Phase 3 and optimize dosing strategies.
• Panelists called for greater collaboration and a reduction in "Me Too" drug development to avoid resource wastage.

Analyst Questions and Answers:

• Question on AI: How is AI reshaping trials? Answer: AI is expected to drive feasibility planning, standardized protocol creation (reducing chaos in inclusion/exclusion criteria), and automated data triage. However, experts warn against over-reliance without human oversight and note that AI requires high-quality data to be effective.
• Question on China: Is China a threat? Answer: Views diverge; some see it as a competitive threat to Western biotech, while others view it as a crucial collaboration partner for faster early-stage data generation, manufacturing scale, and R&D acceleration.
• Question on Patient Recruitment: Why is enrollment difficult? Answer: Barriers include physician burnout from bureaucracy, lack of financial incentives for referrals, complex eligibility criteria, and patients' fear due to poor communication. AI and patient engagement are cited as potential solutions.
• Question on Biomarkers: What drives success? Answer: Biomarkers double the likelihood of drug activity; their integration is critical for defining success in targeted therapies and reducing the need for large Phase 2 studies.

Other Key Points:

• Patient Engagement: There is a strong push to move from tokenistic patient involvement to meaningful co-design of protocols, including quality-of-life endpoints, which can improve recruitment and trial relevance.
• Standardization: A recurring theme is the need for standardized protocols across sponsors to reduce operational friction; AI is suggested as a potential "change agent" to enforce these standards.
• Root Cause Analysis: One panelist identified a lack of venture capital in Europe compared to the US and China as a primary driver of the region's decline in clinical trial activity.
• Regulatory Feedback: Regulators in Europe and the US are showing increased openness to novel trial designs and early-stage engagement, though specific legislative hurdles (like IVDR) remain problematic.